Bristol-Myers, Ono Pharmaceutical deal
Bristol-Myers Squibb and Ono partnered to jointly develop and commercialize multiple products, including Opdivo nivolumab and Yervoy ipilimumab, in Japan, South Korea and Taiwan. The deal also includes BMS’s lirilumab ( BMS-986015; IPH2102), urelumab ( BMS-663513) and BMS-986016. The partners will jointly pursue development of monotherapy and combination regimens of the immunotherapies.
Under the deal, the partners will equally share development costs and commercial profits when Opdivo is used in combination with any BMS products. BMS will fund the substantial majority of development costs and receive the substantial majority of commercial profits when one of its compounds is used as a monotherapy or two of its compounds are used in combination. Ono will fund the substantial majority of development costs and receive the substantial majority of commercial profits when Opdivo is used as a single agent. ...